Clinical applications of reticulocyte hemoglobin indices, including reticulocyte hemoglobin equivalent (Ret-He) and reticulocyte hemoglobin content (CHr), among pregnant and postpartum women: A scoping review and evidence map

Early detection of iron deficiency during pregnancy and the postpartum period, a common condition associated with adverse maternal and neonatal outcomes, remains challenging with conventional iron markers. Reticulocyte hemoglobin indices, including reticulocyte hemoglobin equivalent and reticulocyte hemoglobin content, may enable earlier detection of iron-restricted erythropoiesis. We conducted a scoping review to map the clinical and research applications of these indices in pregnant and postpartum women. Following Joanna Briggs Institute methodology and PRISMA-ScR guidance, we searched PubMed, CENTRAL, Web of Science, and Ichushi Web for studies published from January 1, 1990, to May 31, 2025, and performed an updated search on April 21, 2026, for newly added or indexed records. Eligible studies involved pregnant women or women within 3 months postpartum in whom reticulocyte hemoglobin indices were evaluated for clinical or research purposes. We also constructed an evidence map to visualize the distribution of evidence and research gaps. Thirty-five studies were included. Evidence was most developed for diagnostic accuracy for iron deficiency and associations with iron-related biomarkers. Reticulocyte hemoglobin indices generally showed good diagnostic performance, although reported cut-off values varied widely across studies. Data from mid-to-late pregnancy remained limited. Studies using reticulocyte hemoglobin indices as indicators of response to iron therapy are increasing. Some studies examined longitudinal changes and reference values across pregnancy and the postpartum period; however, these studies were methodologically limited. Three studies examined associations between maternal reticulocyte hemoglobin indices and neonatal parameters, whereas no study evaluated maternal clinical outcomes. Overall, reticulocyte hemoglobin indices appear promising for assessing iron status and monitoring response to iron therapy in perinatal populations. However, substantial heterogeneity in study design, reference standards, and analytical platforms, together with limited longitudinal and outcome-oriented evidence, currently constrains broader clinical implementation.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-13
DOI
https://doi.org/10.1371/journal.pone.0362481
Primary Topic
Iron Metabolism and Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical applications of reticulocyte hemoglobin indices, including reticulocyte hemoglobin equivalent (Ret-He) and reticulocyte hemoglobin content (CHr), among pregnant and postpartum women: A scoping review and evidence map

Yoshimitsu Takahashi, Masaki Mandai, Mayumi Toyama, Takuma Ohsuga et al.
PLoS ONE
Iron Metabolism and Disorders
article

Clinical applications of reticulocyte hemoglobin indices, including reticulocyte hemoglobin equivalent (Ret-He) and reticulocyte hemoglobin content (CHr), among pregnant and postpartum women: A scoping review and evidence map

Yoshimitsu Takahashi, Masaki Mandai, Mayumi Toyama, Takuma Ohsuga, Takeo Nakayama, Miho Egawa, Miki Ohtsuki, Kaori Tsuyuki, Kohei Ida
article en

Abstract

Early detection of iron deficiency during pregnancy and the postpartum period, a common condition associated with adverse maternal and neonatal outcomes, remains challenging with conventional iron markers. Reticulocyte hemoglobin indices, including reticulocyte hemoglobin equivalent and reticulocyte hemoglobin content, may enable earlier detection of iron-restricted erythropoiesis. We conducted a scoping review to map the clinical and research applications of these indices in pregnant and postpartum women. Following Joanna Briggs Institute methodology and PRISMA-ScR guidance, we searched PubMed, CENTRAL, Web of Science, and Ichushi Web for studies published from January 1, 1990, to May 31, 2025, and performed an updated search on April 21, 2026, for newly added or indexed records. Eligible studies involved pregnant women or women within 3 months postpartum in whom reticulocyte hemoglobin indices were evaluated for clinical or research purposes. We also constructed an evidence map to visualize the distribution of evidence and research gaps. Thirty-five studies were included. Evidence was most developed for diagnostic accuracy for iron deficiency and associations with iron-related biomarkers. Reticulocyte hemoglobin indices generally showed good diagnostic performance, although reported cut-off values varied widely across studies. Data from mid-to-late pregnancy remained limited. Studies using reticulocyte hemoglobin indices as indicators of response to iron therapy are increasing. Some studies examined longitudinal changes and reference values across pregnancy and the postpartum period; however, these studies were methodologically limited. Three studies examined associations between maternal reticulocyte hemoglobin indices and neonatal parameters, whereas no study evaluated maternal clinical outcomes. Overall, reticulocyte hemoglobin indices appear promising for assessing iron status and monitoring response to iron therapy in perinatal populations. However, substantial heterogeneity in study design, reference standards, and analytical platforms, together with limited longitudinal and outcome-oriented evidence, currently constrains broader clinical implementation.

PLoS ONEVol. 21(11)
Kyoto University (JP)
Iron Metabolism and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon